By [Your Name/Journalistic Staff]
For over a decade, the landscape of obstructive sleep apnea (OSA) treatment via mandibular advancement devices (MADs) was characterized by a predictable, low-frequency safety profile. Dentists and sleep medicine specialists alike relied on these oral appliances as a stable, well-understood intervention. However, a recent analysis of the Food and Drug Administration’s (FDA) Manufacturer and User Facility Device Experience (MAUDE) database has revealed a startling trend: a massive, tenfold increase in adverse event reports between 2024 and 2025.
This unexpected statistical spike—identified by researchers Sue Ellen Richardson, DDS, DABDSM, FAASM, and Aaron Glick, DDS, FICOI, FAGD, DABDSM—has sent ripples through the dental sleep medicine community. As the industry grapples with the data, experts are asking a critical question: Is this surge a reflection of declining device quality, a byproduct of evolving reporting standards, or an artifact of how modern telehealth companies interact with federal oversight?
The Disruption of the Status Quo: Main Facts
The study, recently published in the Journal of Clinical Sleep Medicine, highlights a dramatic departure from historical norms. Between 2013 and 2023, the MAUDE database recorded a modest average of 41 adverse event reports annually for oral appliances. These reports were typically localized, minor, and centered on biocompatibility—specifically, patient allergic reactions to device materials.
The narrative changed abruptly in 2024. Glick and Richardson’s research identified a 10.1-fold increase in reports during the 2024–2025 period compared to the preceding four years. This shift was not merely numerical; it was qualitative. The nature of the reported issues pivoted from physiological concerns (allergies) to mechanical failures (fractured components).
Despite the alarming volume, the researchers caution that the MAUDE database is a passive surveillance system. It lacks "denominator data"—the total number of devices currently in circulation—which makes it impossible to calculate a true incidence rate of device failure. Nevertheless, the velocity of the change is unprecedented, prompting a closer examination of what happens behind the scenes of medical device manufacturing and distribution.
A Chronological Shift in Reporting
To understand the scope of the increase, the researchers divided the data into two distinct cohorts: Period A (2020–2023) and Period B (2024–2025).
- Period A (2020–2023): The mean annual report volume remained consistent at 42.0. During this time, 78% of reports were categorized as allergic or biocompatibility reactions, while only 8.9% concerned broken or fractured devices.
- Period B (2024–2025): The mean annual volume surged to 423.5. In the calendar year 2025 alone, 662 reports were filed. Most significantly, the profile flipped: 91.6% of reports in this period involved broken or fractured devices, while allergic reactions plummeted to just 4.8% of the total.
This chronological divide suggests that either the manufacturing quality of these devices suffered a sudden, systemic decline, or that the mechanisms for identifying and reporting these fractures underwent a fundamental shift.
Analyzing the Data: Manufacturer and Distribution Factors
A granular look at the data reveals that a single product line, the "Silent Nite" manufactured by Prismatik Dentalcraft (a subsidiary of Glidewell Dental), accounted for 97.6% of the reports in the post-2024 period. The vast majority of these reports involved fractures in the anchor or hinge components.
The Manufacturer’s Defense
Shelly Gallup, senior vice president of regulatory affairs and quality assurance at Prismatik Dentalcraft, argues that the surge is a result of administrative transparency rather than product failure. According to Gallup, the company implemented a centralized, rigorous complaint intake process in 2024. By expanding their internal review and ensuring that every minor complaint was processed as a formal Medical Device Report (MDR), the volume of submissions to the FDA naturally skyrocketed.
Gallup further emphasizes that Prismatik operates under the strict requirements of 21 C.F.R. Part 803, which mandates reporting for FDA-registered manufacturers. She suggests that many smaller dental laboratories, which also produce oral appliances, may not be subject to the same level of regulatory scrutiny or reporting infrastructure, leading to a "data gap" where their event rates go unrecorded in the MAUDE database.
The Role of Telehealth
The emergence of direct-to-consumer (DTC) and telehealth-integrated models has added another layer of complexity. Critics of these models have long expressed concerns about the lack of in-person oversight. However, proponents like Peter Balacky, DDS, dental director at Daybreak, argue that digital models actually improve reporting accuracy.
Daybreak, which was associated with a segment of the reports in the study, maintains that their model creates a continuous feedback loop. Because their patients are monitored through a dedicated digital portal with frequent touchpoints, device failures are captured more effectively than in traditional, fragmented care pathways. Balacky notes that in a traditional practice, a broken hinge might be repaired in-house and never formally reported to the FDA. In a digital-first model, the protocol requires systematic logging of these events, leading to a higher—and perhaps more accurate—reporting rate.
Official Perspectives and Regulatory Limitations
The FDA has long maintained that the MAUDE database is not a substitute for rigorous, large-scale clinical registries. The agency explicitly cautions against using this data to establish or compare event rates between manufacturers.
The researchers themselves, Glick and Richardson, acknowledge this limitation. "We don’t know the denominator," says Richardson. "Without knowing how many thousands of devices are in use, we cannot say if these failures are statistically significant in terms of risk."
The absence of denominator data means that while we see a "spike," we cannot distinguish between an increase in device failure and an increase in reporting compliance. The latter is a positive development for public health, even if it creates the appearance of a safety crisis in a public-facing database.
Clinical Implications: Is the Treatment Still Safe?
Despite the noise in the data, the clinical consensus remains clear: mandibular advancement devices are safe and effective. The majority of reported fractures described in the study occurred without causing patient injury.
The study also highlighted a peculiar gap: clinical literature is dominated by concerns about long-term physiological side effects—such as bite changes, temporomandibular disorder (TMD), and periodontal shifts. Yet, these are rarely found in the MAUDE database. Experts suggest this is likely because these issues are managed successfully in-office by dentists. When a patient develops a minor bite adjustment issue, it is a clinical management task, not a "device failure" that requires a federal report.
This creates a paradox: the MAUDE database is an excellent tool for tracking mechanical durability, but it is a poor instrument for measuring the clinical, patient-centered success or failure of a treatment protocol.
Looking Ahead: Toward Better Surveillance
The surge in 2024 and 2025 reporting should be viewed as a signal, not a verdict. It is a clarion call for the dental sleep medicine industry to develop more robust, transparent, and standardized reporting mechanisms.
- Standardized Reporting: The industry must reconcile the difference between large-scale manufacturers like Prismatik and smaller dental labs to ensure that "reporting compliance" does not unfairly penalize companies that prioritize transparency.
- Clinical Registries: The profession should move toward the creation of dedicated sleep medicine device registries that track outcomes, not just mechanical failures.
- Educational Outreach: Dentists must be better equipped to distinguish between a "reportable event" and a routine clinical adjustment, ensuring that the FDA receives data that is actually actionable.
As Glick noted, "What we have done is present some of the information that we found as an early sign." The future of OSA treatment depends on the ability to interpret these signs correctly, ensuring that as technology and distribution models evolve, patient safety remains the primary, non-negotiable metric.
For now, patients and providers can rest assured that while the reporting numbers have changed, the fundamental therapeutic value of oral appliances for the treatment of obstructive sleep apnea remains a gold-standard, life-improving intervention. The "dramatic change" in the MAUDE database is likely a growing pain of an industry shifting toward more rigorous, tech-enabled, and transparent compliance—a change that, in the long run, will only strengthen the field.
